ENDP - Eagle Pharma did not infringe on Endo's vasopressin patents - appeals court

• Eagle Pharmaceuticals ( NASDAQ: EGRX ) announced Thursday that a federal appeals court ruled the company's blood pressure therapy vasopressin did not infringe on any of the patents claimed by Par Pharmaceutical, Inc., a unit of the generic drug maker Endo International ( ENDP ).
• The decision affirms a District Court ruling after Par alleged in a 2018 lawsuit that Eagle ( EGRX ) infringed several of its patents.
• Subsequently, the U.S. District Court for the District of Delaware held that Eagle ( EGRX ) did not infringe any of the patents, and Par appealed. Eagle ( EGRX ) won FDA approval for its generic vasopressin in December.
• The injection is indicated to raise blood pressure in adults with vasodilatory shock, and the drug added $11.3M in sales for Eagle ( EGRX ) during the second quarter of 2022.

For further details see: